- Home
- CVM vs IMMX Comparison
CVM vs IMMX Comparison
Compare CVM & IMMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CVM
- IMMX
- Stock Information
- Founded
- CVM 1983
- IMMX 2014
- Country
- CVM United States
- IMMX United States
- Employees
- CVM N/A
- IMMX N/A
- Industry
- CVM Biotechnology: Biological Products (No Diagnostic Substances)
- IMMX Medicinal Chemicals and Botanical Products
- Sector
- CVM Health Care
- IMMX Health Care
- Exchange
- CVM Nasdaq
- IMMX Nasdaq
- Market Cap
- CVM 40.1M
- IMMX 61.1M
- IPO Year
- CVM 1987
- IMMX 2021
- Fundamental
- Price
- CVM $0.71
- IMMX $2.12
- Analyst Decision
- CVM
- IMMX Strong Buy
- Analyst Count
- CVM 0
- IMMX 1
- Target Price
- CVM N/A
- IMMX $7.00
- AVG Volume (30 Days)
- CVM 997.7K
- IMMX 247.3K
- Earning Date
- CVM 02-12-2025
- IMMX 11-12-2024
- Dividend Yield
- CVM N/A
- IMMX N/A
- EPS Growth
- CVM N/A
- IMMX N/A
- EPS
- CVM N/A
- IMMX N/A
- Revenue
- CVM N/A
- IMMX N/A
- Revenue This Year
- CVM N/A
- IMMX N/A
- Revenue Next Year
- CVM $3,412.81
- IMMX $200.00
- P/E Ratio
- CVM N/A
- IMMX N/A
- Revenue Growth
- CVM N/A
- IMMX N/A
- 52 Week Low
- CVM $0.49
- IMMX $1.26
- 52 Week High
- CVM $3.15
- IMMX $7.10
- Technical
- Relative Strength Index (RSI)
- CVM 51.45
- IMMX 51.87
- Support Level
- CVM $0.60
- IMMX $2.04
- Resistance Level
- CVM $0.82
- IMMX $2.44
- Average True Range (ATR)
- CVM 0.12
- IMMX 0.31
- MACD
- CVM 0.01
- IMMX -0.03
- Stochastic Oscillator
- CVM 36.28
- IMMX 30.12
About CVM Cel-Sci Corporation
CEL-SCI Corp is a player in the biotechnology sector. It is engaged in the research and development at developing the treatment of cancer and other diseases by using the immune system. The Company's core capabilities that include are drug discovery, research, development and manufacturing of complex biological substances. It is focused on the development of Multikine (Leukocyte Interleukin, Injection), investigational immunotherapy under development for the treatment of certain head and neck cancers, and anal warts or cervical dysplasia.
About IMMX Immix Biopharma Inc.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.